Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

Biomarker analyses provided proof of a mechanism during combination therapy.Yap and his colleagues observed increased CD8+ T cell infiltration and activation in tumors, reduced the regulatory T ...

Astellas Pharma presented new results from cohort 9 of the EV-202 trial at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany, from 17 to 21 October. Conducted in ...

Merck & Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s ...

KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...

Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with the immunotherapy Keytruda (pembrolizumab), has been associated with a 49% ...

Applications based on Phase 3 KEYNOTE-905 results showing the combination improved event-free survival by 60%, reduced the risk of death by 50% and increased pathologic complete response rates by 48% ...

The FDA approved Merck's Keytruda Qlex, a new under-the-skin version of the cancer drug that can be injected in just 1-2 minutes, offering faster and more convenient treatment than traditional IV ...